default author photo

Giuseppe Fotia

Fondazione IRCCS Istituto Nazionale dei Tumori

SCHOLARLY PAPERS

4

DOWNLOADS

180

TOTAL CITATIONS

0

Scholarly Papers (4)

1.

Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2

Number of pages: 34 Posted: 12 Sep 2025
Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Università di Padova - Dipartimento di Scienze Chirurgiche, European Institute of Oncology (IEO) IRCCS - Division of New Drugs and Early Drug Development for Innovative Therapies, Baylor College of Medicine, Sapienza University of Rome, University of Genova - Department of Internal Medicine and Medical Specialties (DiMI), Fondazione IRCCS Policlinico San Matteo, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, ASST Papa Giovanni XXIII, affiliation not provided to SSRN, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, Azienda Socio Sanitaria Territoriale Lariana, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori and Fondazione IRCCS Istituto Nazionale dei Tumori
Downloads 55 (1,041,696)

Abstract:

Loading...

HR+/HER2- advanced breast cancer, CDK4/6 inhibitors, Real-world, progression-free survival, Lobular histology, PALMARES-2

2.

Adjuvant Ovarian Function Suppression and Aromatase Inhibitors in Premenopausal Patients with Hormone Receptor And Her2 Positive Breast Cancer, by Timing of Chemotherapy and Trastuzumab and Response to Neoadjuvant Therapy

Number of pages: 22 Posted: 16 Jul 2025
Technion-Israel Institute of Technology - Rambam Health Care Campus, KU Leuven - University Hospitals Leuven, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, University of Gothenburg - Sahlgrenska University Hospital, University of Genova - Department of Internal Medicine and Medical Specialties (DiMI), affiliation not provided to SSRN, affiliation not provided to SSRN, Université de Lille - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, Institute of Oncology, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, Santa Maria Local Health Unit, affiliation not provided to SSRN, affiliation not provided to SSRN, HFR Fribourg Cantonal Hospital, Bank of Cyprus Oncology Centre, Institut National de la Santé et de la Recherche Médicale (INSERM), Istinye University, Maastricht University, AZ Turnhout, AZ Groeninge, Hebrew University of Jerusalem - Shaare Zedek Medical Center, affiliation not provided to SSRN, Hebrew University of Jerusalem - The Sharett Institute of Oncology, IRCCS Ospedale Policlinico San Martino, Technion-Israel Institute of Technology - Rambam Health Care Campus, KU Leuven - Department of Gynecologic Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, Technion-Israel Institute of Technology - Rambam Health Care Campus, affiliation not provided to SSRN, Istinye University, European Commission, Joint Research Centre and Netherlands Cancer Institute
Downloads 52 (1,041,696)

Abstract:

Loading...

Ovarian function suppression, HER2 positive, adjuvant endocrine therapy, aromatase inhibitors, tamoxifen, LHRH agonists, neoadjuvant, residual disease, pathological complete response

EVENT-FREE SURVIVAL AFTER STEREOTACTIC BODY RADIATION THERAPY FOR OLIGOPROGRESSIVE METASTATIC BREAST CANCER

Number of pages: 22 Posted: 13 Oct 2025
Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, IEO Istituto Europeo di Oncologia IRCCS, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori and Fondazione IRCCS Istituto Nazionale dei Tumori
Downloads 27 (1,400,723)

Abstract:

Loading...

Breast Cancer, oligoprogression, Progression-directed radiation therapy, Event-free survival

EVENT-FREE SURVIVAL AFTER STEREOTACTIC BODY RADIATION THERAPY FOR OLIGOPROGRESSIVE METASTATIC BREAST CANCER

Number of pages: 21 Posted: 12 Sep 2025
Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, IEO Istituto Europeo di Oncologia IRCCS, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori and Fondazione IRCCS Istituto Nazionale dei Tumori
Downloads 16 (1,548,841)

Abstract:

Loading...

breast cancer, Oligoprogression, Progression-directed radiation therapy, Event-free survival

Development of a machine learning model to guide further metastatic biopsy decision in patients with HER2-0 status on both primary breast cancer and first biopsied metastatic site: who should undergo a repeated biopsy to detect HER2-low gain?

Number of pages: 17 Posted: 12 Jan 2026
affiliation not provided to SSRN, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, affiliation not provided to SSRN, London School of Hygiene & Tropical Medicine - Cancer Survival Group, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Sapienza University of Rome, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, University of Padua - Department of Medicine, Università di Padova - Dipartimento di Scienze Chirurgiche and affiliation not provided to SSRN
Downloads 19 (1,513,226)

Abstract:

Loading...

Breast Cancer, HER2-low, machine-learning

Development of a machine learning model to guide further metastatic biopsy decision in patients with HER2-0 status on both primary breast cancer and first biopsied metastatic site: who should undergo a repeated biopsy to detect HER2-low gain?

Number of pages: 17 Posted: 14 Jan 2026
affiliation not provided to SSRN, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, affiliation not provided to SSRN, London School of Hygiene & Tropical Medicine - Cancer Survival Group, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Sapienza University of Rome, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, University of Padua - Department of Medicine, Università di Padova - Dipartimento di Scienze Chirurgiche and affiliation not provided to SSRN
Downloads 11 (1,598,105)

Abstract:

Loading...

breast cancer, HER2-low, machine-learning